Alexander Jarrett Summers

Alexander Jarrett Summers

Auto-generated profile, based on publicly available information

Alexander Jarrett Summers

University of Arizona 475 North Fifth Street

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2024 in Nature
Verified
Journal Article
Open access
PDF file
CJChristopher W. Jones
Christopher W. Jones
EOEliah G. Overbey
Eliah G. Overbey
JLJerome Lacombe
Jerome Lacombe
AEAdrian J. Ecker
Adrian J. Ecker
CMCem Meydan
Cem Meydan
Christopher MasonChristopher Mason
Christopher Mason
Human spaceflight has historically been managed by government agencies, such as in the NASA Twins Study1, but new commercial spaceflight opportunities have opened spaceflight to a broader population. In 2021, the SpaceX Inspiration4 mission launched the first all-civilian crew to low Earth orbit, which included the youngest American astronaut (aged 29), new in-flight experimental technologies (handheld ultrasound imaging, smartwatch wearables and immune profiling), ocular alignment measurements and new protocols for in-depth, multi-omic molecular and cellular profiling. Here we report the primary findings from the 3-day spaceflight mission, which induced a broad range of physiological and stress responses, neurovestibular changes indexed by ocular misalignment, and altered neurocognitive functioning, some of which match those of long-term spaceflight2, but almost all of which did not differ from baseline (pre-flight) after return to Earth. Overall, these preliminary civilian spaceflight data suggest that short-duration missions do not pose a significant health risk, and moreover present a rich opportunity to measure the earliest phases of adaptation to spaceflight in the human body at anatomical, cellular, physiological and cognitive levels. Finally, these methods and results lay the foundation for an open, rapidly expanding biomedical database for astronauts3, which can inform countermeasure development for both private and government-sponsored space missions.

27 February 2023 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
SASupriya Atta
Supriya Atta
ACAidan J. Canning
Aidan J. Canning
RORen Odion
Ren Odion
HWHsin-Neng Wang
Hsin-Neng Wang
DHDerrick Hau
Derrick Hau
TVTuan Vo-Dinh
Tuan Vo-Dinh

29 September 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
SASupriya Atta
Supriya Atta
YZYuanhao Zhao
Yuanhao Zhao
SSSebastian Sanchez
Sebastian Sanchez
DSDeven Seedial
Deven Seedial
JDJasmine Pramila Devadhasan
Jasmine Pramila Devadhasan
TVTuan Vo-Dinh
Tuan Vo-Dinh

30 August 2022 in ACS Omega
Verified
Journal Article
Open access
ASAlexander J. Summers
Alexander J. Summers
JDJasmine P. Devadhasan
Jasmine P. Devadhasan
Jian GuJian Gu
Jian Gu
DMDouglas C. Montgomery
Douglas C. Montgomery
BFBrittany Fischer
Brittany Fischer
FZFrederic Zenhausern
Frederic Zenhausern
Antibody microarrays have proven useful in immunoassay-based point-of-care diagnostics for infectious diseases. Noncontact piezoelectric inkjet printing has advantages to print antibody microarrays on nitrocellulose substrates for this application due to its compatibility with sensitive solutions and substrates, simple droplet control, and potential for high-capacity printing. However, there remain real-world challenges in printing such microarrays, which motivated this study. The effects of three concentrations of capture antibody (cAb) reagents and nozzle hydrostatic pressures were chosen to investigate three responses: the number of printed membrane disks, dispensing performance, and microarray quality. Printing conditions were found to be most ideal with 5 mg/mL cAb and a nozzle hydrostatic pressure near zero, which produced 130 membrane disks in a single print versus the 10 membrane disks per print before optimization. These results serve to inform efficient printing of antibody microarrays on nitrocellulose membranes for rapid immunoassay-based detection of infectious diseases and beyond.

8 July 2025 in Analytica Chimica Acta
Verified
Journal Article
Closed access
SASupriya Atta
Supriya Atta
YZYuanhao Zhao
Yuanhao Zhao
SSSebastian Sanchez
Sebastian Sanchez
SYSabina V. Yampolsky
Sabina V. Yampolsky
VBVanessa K. Berner
Vanessa K. Berner
TVTuan Vo-Dinh
Tuan Vo-Dinh

1 July 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
ASAlexander J. Summers
Alexander J. Summers
HHHaydon J. Hill
Haydon J. Hill
JDJasmine P. Devadhasan
Jasmine P. Devadhasan
JGJian Gu
Jian Gu
VBVanessa Berner
Vanessa Berner
FZFrederic Zenhausern
Frederic Zenhausern
Rift Valley fever (RVF) is a vector-borne, zoonotic infectious disease with a proven history of morbidity and mortality in both humans and animals. Rift Valley fever virus (RVFV) is categorized as a high-priority biothreat agent by the Centers for Disease Control and Prevention and poses a serious national threat due to its ease of dissemination and potential for social disruption. RVF often presents as a febrile disease without specific symptoms, making early-stage detection particularly challenging. As such, it is critical that rapid, sensitive, and specific diagnostics are available for the detection of RVFV. While lateral flow immunoassays (LFIs) have been developed and validated for point-of-care (POC) diagnostics, vertical flow immunoassays (VFIs) provide enhanced analytical sensitivity and are equally suitable for POC use. In this study, we developed a VFI system for the detection of RVFV, achieving a limit of detection of 0.78 ng/mL, which is a 2.5-fold increase in analytical sensitivity compared to an LFI prototype. Furthermore, minimal cross-reactivity was demonstrated when performing the assay with target analytes of other high-priority biothreats and one other common viral nucleoprotein. This high-sensitivity VFI has the potential to prove useful for the detection of RVFV and other high-priority biothreat agents at the POC. IMPORTANCE: In this study, we have developed a rapid, sensitive vertical flow immunoassay (VFI) for the detection of Rift Valley fever virus (RVFV) in spiked human serum. The prototype diagnostic described in this research was shown to be more sensitive than traditional methods, such as lateral flow dipstick tests. Moreover, the VFI is readily deployable at the point of care in resource-limited settings. The ability of the described diagnostic to accurately and rapidly detect RVFV in samples could expedite the delivery of life-saving care and thus improve patient outcomes.